TrialBlood2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Vaishali Sanchorawala et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
57 papers cite it
this paperpooled ittrialcites it